GRANULES:NSE-Granules India Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 310.65

Change

0.00 (0.00)%

Market Cap

INR 77.13B

Volume

1.84M

Avg Analyst Target

INR 350.25 (+12.75%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


GRANULES Stock Forecast & Price:
Based on the Granules India Limited stock forecasts from 4 analysts, the average analyst target price for Granules India Limited is INR 350.25 over the next 12 months. Granules India Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Granules India Limited is Slightly Bullish , which is based on 6 positive signals and 4 negative signals. At the last closing, Granules India Limited’s stock price was INR 310.65. Granules India Limited’s stock price has changed by -0.10% over the past week, +1.75% over the past month and -13.88% over the last year.

About Granules India Limited (GRANULES:NSE)

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, Africa, the Middle East, and internationally. The company's APIs in various ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-14 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

N/A

INR2,191.67B 56.39 28.73
DIVISLAB:NSE Divi's Laboratories Limited

N/A

INR989.19B 33.41 25.55
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

N/A

INR709.90B 23.93 13.20
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

N/A

INR523.65B 65.42 25.61
PEL:NSE Piramal Enterprises Limited

N/A

INR427.41B 22.81 11.63
ALKEM:NSE Alkem Laboratories Limited

N/A

INR355.67B 21.61 21.38
AUROPHARMA:NSE Aurobindo Pharma Limited

N/A

INR347.73B 13.13 7.15
LUPIN:NSE Lupin Limited

N/A

INR310.45B 25.10 -92.56
LAURUSLABS:NSE Laurus Labs Limited

N/A

INR304.23B 36.46 21.64
IPCALAB:NSE IPCA Laboratories Limited

N/A

INR235.45B 32.68 20.48

ETFs Containing GRANULES

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.60% 82% B- 49% F
Dividend Return 0.30% 28% F 16% F
Total Return -7.30% 82% B- 49% F
Trailing 12 Months  
Capital Gain -13.88% 69% D+ 31% F
Dividend Return 0.35% 33% F 18% F
Total Return -13.53% 71% C- 30% F
Trailing 5 Years  
Capital Gain 167.57% 81% B- 83% B
Dividend Return 4.74% 73% C 59% F
Total Return 172.31% 81% B- 83% B
Average Annual (5 Year Horizon)  
Capital Gain 46.29% 80% B- 81% B-
Dividend Return 0.65% 67% D+ 49% F
Total Return 46.94% 80% B- 81% B-
Risk Return Profile  
Volatility (Standard Deviation) 82.46% 29% F 27% F
Risk Adjusted Return 56.92% 75% C 80% B-
Market Capitalization 77.13B 75% C 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.38 68% D+ 54% F
Price/Book Ratio 2.90 49% F 38% F
Price / Cash Flow Ratio 23.23 44% F 28% F
EV/EBITDA 11.15 62% D- 45% F
Management Effectiveness  
Return on Equity 17.34% 72% C- 70% C-
Return on Invested Capital 12.67% 63% D 70% C-
Return on Assets 8.83% 71% C- 78% C+
Debt to Equity Ratio 9.04% 54% F 56% F
Technical Ratios  
Dividend Yield 0.99% 63% D 52% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.50 77% C+ 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.